FindMyRecallSubscribe
Class I: serious health riskTerminated

Spectrum Laboratory Products Epinephrine Recall

Epinephrine (L-Adrenaline), USP, CAS 51-43-4, Packaged in amber glass bottles in a vacu…

Spectrum Laboratory Products, Inc. · New Brunswick, NJ

Risk level
Class I
Reported by FDA
Feb 1, 2023
Recall ID
D-0180-2023
Check your lot numberHow we source this data

Summary

Spectrum Laboratory Products recalled Epinephrine starting Dec 19, 2022. The FDA classified it as Class I (serious health risk) and published enforcement report D-0180-2023 on Feb 1, 2023. Reason: Discoloration: Product complaints of the repackaged Epinephrine API being discolored which could result in less effective product. Status: Terminated.

Why it was recalled

Discoloration: Product complaints of the repackaged Epinephrine API being discolored which could result in less effective product

Product description

Epinephrine (L-Adrenaline), USP, CAS 51-43-4, Packaged in amber glass bottles in a vacuum sealed pouch as (a)100 G; (b)1 G, (c) 25 G, (d) 5 G; Rx only. Repackaged by Spectrum Chemical Mfg. Corp. Gardena, CA 90248; New Brunswick, NJ 08901.

Lot numbers, UPCs & expiration codes

Lot # (a) (b) (c) (d) lot 2KL0353, EXP 30-Sep-2023; 2KF0151, EXP 31-Mar-2023

Where it was sold

Nationwide in the USA, Puerto Rico and Canada

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0180-2023
Classification
Class I
Status
Terminated
Recall initiated
Dec 19, 2022
FDA report date
Feb 1, 2023
Quantity
7 x 100G; 17 x 1G; 6 x 25G; 20 x 5G
Recall type
Voluntary: Firm initiated
Recalling firm
Spectrum Laboratory Products, Inc.

Original FDA data

Every field from FDA enforcement report D-0180-2023, exactly as published.

Show all FDA fields
City
New Brunswick
State
NJ
Status
Terminated
Country
United States
Event ID
91381
Address
755, 769 And 777 Jersey Ave
Code information
Lot # (a) (b) (c) (d) lot 2KL0353, EXP 30-Sep-2023; 2KF0151, EXP 31-Mar-2023
Postal code
08901-3605
Report date
Feb 1, 2023
Product type
Drugs
Recall number
D-0180-2023
Classification
Class I
Recalling firm
Spectrum Laboratory Products, Inc.
Product quantity
7 x 100G; 17 x 1G; 6 x 25G; 20 x 5G
Termination date
Aug 19, 2025
Reason for recall
Discoloration: Product complaints of the repackaged Epinephrine API being discolored which could result in less effective product
Voluntary / mandated
Voluntary: Firm initiated
Product description
Epinephrine (L-Adrenaline), USP, CAS 51-43-4, Packaged in amber glass bottles in a vacuum sealed pouch as (a)100 G; (b)1 G, (c) 25 G, (d) 5 G; Rx only. Repackaged by Spectrum Chemical Mfg. Corp. Gardena, CA 90248; New Brunswick, NJ 08901.
Distribution pattern
Nationwide in the USA, Puerto Rico and Canada
Recall initiation date
Dec 19, 2022
Initial firm notification
Letter
Center classification date
Jan 25, 2023

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0180-2023, published Feb 1, 2023. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls